Therapeutic administration of pegfilgrastim instead of prophylactic use

Anticancer Research

Volumn 25, Issue 3 C, 2005, Pages 2445-2448

  Stathopoulos, George P ^a,b   Dimou, Evangelini ^a   Stathopoulos, John ^a   Xynotroulas, John ^a  

^a Errikos Dunant Hospital   (Greece)

^b NONE   (Greece)

Author keywords

Neutropenia leukopenia; Pegfilgrastim

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EPIRUBICIN; GEMCITABINE; IRINOTECAN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG ABSORPTION; DRUG SAFETY; FEMALE; HEAD AND NECK CANCER; HUMAN; LEUKOCYTE; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NEUTROPENIA; OVARY CANCER; PANCREAS CANCER; PRIORITY JOURNAL; STOMACH CANCER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; FILGRASTIM; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA;

EID: 22944434888     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Crawford J, Ozer H, Stoller R et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325: 164, 1991.
2. Le Chevalier T, Brisgand D, Donillard JY et al: Randomized study of vinorelbine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 cases. J Clin Oncol 12: 360-367, 1994.
3. Non-Small-Cell Lung Cancer Collaborative Groups: Chemotherapy in non-small-cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 311: 899-909, 1995.
4. Livingeton RB, Ellis GK, Gralow JR et al: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400, 1997.
5. Belani CP, Keams CM, Zuhowski EG et al: Phase I trial including pharmacokinetic and pharmacodynamic correlations of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 17: 676-684, 1999.
6. Sadler AB, Nemunaitis J, Dehnam C et al: Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18: 122-130, 2000.
7. Kornek G, Ulrich-Pur H, Penz M et al: Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor. J Clin Oncol 19: 621-627, 2001.
8. Groopman JE, Molina JM and Scadden DT: Hematopoietic growth factors: biology and clinical application. N Engl J Med 321: 1449-1459, 1989.
9. Welte K, Gabrilove J, Bronchud MH et al: Filgrastim (r-metHu G-CSF): the first 10 years. Blood 88: 1907-1929, 1996.
10. Maher DW, Graham JL, Green M et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia: a double-blind, placebo-controlled trial. Ann Intern Med 121: 492-501, 1994.
11. Mayordomo JI, Rivera F, Diaz-Puente MT et al: Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors. J Natl Cancer Inst 87: 803-808, 1995.
12. Garcia-Carbonero R, Mayardomo JI, Tornamira MV et al: Granulocyte colony-stimulating factor in the treatment of high-risk febrile neutropenia: a multicenter randomized trial. J Natl Cancer Inst 93: 31-38, 2001.
13. Crino L, Scagliotti G, Maragolo M et al: Cisplatin gemcitabine combination in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol 15: 297-303, 1997.
14. Huizing MT, Giaccone G, Van Warmerdam LJC et al: Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 15: 317-329, 1997.
15. 2) plus carboplatin in non-small-cell lung cancer: a randomized study. Semin Oncol 24(suppl 12): 12-30s 12-33, 1997.
16. Iaffaioli RV, Tortoriello A, Facchini G et al: Phase I-II study of gemcitabine and carboplatin in stage IIIb-IV non-small-cell lung cancer. J Clin Oncol 17: 921-926, 1999.
17. Androulakis N, Kouroussis C, Kakolyris S et al: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin-or-docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9: 1127-1130, 1998.
18. Kouroussis C, Androulakis N, Kakolyris S et al: First-line treatment of advanced non-small-cell lung carcinoma with docetaxel and vinorelbine. Cancer 83: 2083-2090, 1998.
19. Miller VA, Krug LM, Ng KK et al: Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J Clin Oncol 18: 1346-1350, 2000.
20. Monnier A, Riviere A, Donillard JY et al: Phase II study of docetaxel (taxotere) and vinorelbine in chemotherapy naïve patients with advanced non-small-cell lung carcinoma (NSCLC). Proc Am Soc Clin Oncol 15: 378, 1996. (abstr 1129)
21. Lorusso V, Carpagnano F, Frasci G et al: Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small-cell lung cancer. J Clin Oncol 18: 405-41, 2000.
22. Molineux G, Kinstler O, Briddell B et al: A new form of filgrastim with sustained duration in vivo and enhanced ability to mobilize PBBC in both mice and humans. Exp Hematol 27: 1724-1734, 1999.
23. Johnston E, Crawford J, Blackwell S et al: Randomized dose-escalating study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 18: 2522-2528, 2000.
24. Holmes FA, Jones SE, OYShaughnessy JA et al: Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study on women with breast cancer. Ann Oncol 13: 903-909, 2002.
25. Holmes FA, O'Shaughnessy JA, Vukeljas et al: Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy patients with high-risk stage II or stage III/IV breast cancer. J Clin Oncol 20: 727-731, 2002.